Loading…
Novartis AG is projected to rise to $186.93 by 2027, a +24% move from its current price of $151.12. NVS is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $149.73 | $151.18 | $152.65 | +0.04% |
| May 30 | $149.20 | $151.24 | $153.32 | +0.08% |
| May 31 | $148.80 | $151.30 | $153.85 | +0.12% |
| Jun 1 | $148.48 | $151.37 | $154.31 | +0.16% |
| Jun 2 | $148.20 | $151.43 | $154.73 | +0.20% |
| Jun 3 | $147.95 | $151.49 | $155.11 | +0.24% |
| Jun 4 | $147.74 | $151.55 | $155.47 | +0.29% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $147.74 | $151.55 | $155.47 | +0.29% |
| Week 2 | $146.60 | $151.98 | $157.57 | +0.57% |
| Week 3 | $145.83 | $152.42 | $159.30 | +0.86% |
| Week 4 | $145.25 | $152.85 | $160.85 | +1.15% |
| Week 5 | $144.79 | $153.29 | $162.29 | +1.44% |
| Week 6 | $144.42 | $153.73 | $163.64 | +1.73% |
| Week 7 | $144.11 | $154.17 | $164.93 | +2.02% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Novartis AG is a healthcare company that researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. It focuses on therapeutic areas including cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology, with a broad portfolio of medicines. The roster includes Entresto, Cosentyx, Kisqali, Promacta/Revolade, Tafinlar+Mekinist, Jakavi, Tasigna, Xolair, Ilaris, Pluvicto, Sandostatin SC and Sandostatin LAR, Zolgensma, Lucentis, Leqvio, Lutathera, Scemblix, and Fabhalta, and it holds a license with Alnylam Pharmaceuticals to develop Leqvio (inclisiran) for reducing LDL cholesterol.
Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Novartis AG (NVS) is a large healthcare company with a current price of $152.01 and a market cap of $290.05B. It ranks 46 by market capitalization. The stock operates within a defined price framework, with a 30-day range spanning from $142.24 to $162.46.
The current price sits near the forecasted 2026 average, reflecting a close alignment between recent trading levels and near-term projections. Overall, the long-run outlook shown in the forecast indicates meaningful upside through subsequent years, contingent on market conditions.
A major floor 7.6% below — a decisive break under it would weaken the trend.
The nearest floor, 5.4% below — buyers have tended to step in here.
Price is pressing into resistance (0.6% away) — a breakout level to watch.
A major ceiling 11.6% above — clearing it would confirm fresh momentum.
Key NVS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NVS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $151.23 | Sell | $150.95 | Buy |
| MA 10 | $150.33 | Buy | $150.20 | Buy |
| MA 20 | $148.20 | Buy | $149.44 | Buy |
| MA 50 | $149.57 | Buy | $149.89 | Buy |
| MA 100 | $151.82 | Sell | $148.11 | Buy |
| MA 200 | $140.30 | Buy | $141.13 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.89 | Neutral |
| Stoch RSI (14) | 80.67 | Sell |
| CCI (20) | 90.07 | Neutral |
| Williams %R (14) | -13.13 | Info |
| MACD (12,26,9) | 0.63 | Buy |
| ROC (12) | 3.49 | Buy |
| Bollinger %B (20,2) | 0.79 | Neutral |
| Stochastic %K (14) | 86.87 | Sell |
| TRIX (15) | -0.02 | Sell |
| Awesome (5,34) | 2.30 | Buy |
| Ultimate (7,14,28) | 68.59 | Neutral |
| Momentum (10) | 2.96 | Buy |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 151.89 | Sell |
| ADX (14) | 11.63 | Neutral |
| ATR (14) | 1.31 | Info |
The 30-day technical picture for Novartis AG is bullish. The RSI(14) stands at 60, and the price is trading above both the SMA50 at $149.70 and the SMA200 at $139.95, which supports a constructive near-term bias. The stock is expected to encounter resistance near $154.47 as a key hurdle, with support around $142.94 providing a floor for pullbacks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $137.91 | $151.12 | $207.15 | 0% | Neutral | |
| $152.71 | $186.93 | $239.52 | +24% | Bullish | |
| $182.57 | $227.56 | $299.19 | +51% | Bullish | |
| $215.59 | $272.78 | $366.11 | +81% | Bullish | |
| $243.25 | $311.89 | $426.01 | +106% | Bullish | |
| $260.86 | $338.51 | $469.56 | +124% | Bullish | |
| $272.14 | $357.10 | $502.32 | +136% | Bullish | |
| $302.78 | $401.46 | $571.96 | +166% | Bullish | |
| $314.15 | $420.65 | $606.39 | +178% | Bullish | |
| $340.92 | $460.79 | $671.59 | +205% | Bullish | |
| $494.00 | $696.29 | $1,063.18 | +361% | Bullish | |
| $1,007.57 | $1,522.86 | $2,491.81 | +908% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $137.91 | $151.12 | $177.44 | +0.00% |
| June 2026 | $133.91 | $156.21 | $185.76 | +3.37% |
| July 2026 | $133.68 | $156.84 | $188.27 | +0.40% |
| August 2026 | $134.28 | $158.26 | $191.36 | +0.90% |
| September 2026 | $138.84 | $164.24 | $199.77 | +3.78% |
| October 2026 | $141.21 | $167.61 | $204.97 | +2.05% |
| November 2026 | $139.51 | $166.10 | $204.08 | -0.90% |
| December 2026 | $140.58 | $167.84 | $207.15 | +1.05% |
Click any year to see its month-by-month NVS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect NVS to range from $137.91 to $207.15 through 2026. The $151.12 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The NVS price prediction for 2027 points to an average of $186.93 (low $152.71, high $239.52) — a potential gain of +24% on today's $151.12. Buyers look set to stay in control over this stretch.
In 2028, NVS is projected to trade between $182.57 and $299.19, averaging $227.56 — a potential gain of +51% from today's $151.12. That is up +22% on the projected 2027 average. Momentum favours further upside here.
Novartis AG's 2029 outlook centres on $272.78, within a $215.59 to $366.11 range. That is up +20% on the projected 2028 average. That marks a +81% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, NVS could reach as high as $426.01, with a base case around $311.89 and support toward $243.25 — roughly +106% from $151.12. Momentum favours further upside here.
Expect NVS to range from $260.86 to $469.56 through 2031. The $338.51 average target implies a +124% move from current prices. That is up +9% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The NVS price prediction for 2032 points to an average of $357.10 (low $272.14, high $502.32) — a potential gain of +136% on today's $151.12. Momentum favours further upside here.
In 2033, NVS is projected to trade between $302.78 and $571.96, averaging $401.46 — a potential gain of +166% from today's $151.12. That is up +12% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Novartis AG's 2034 outlook centres on $420.65, within a $314.15 to $606.39 range. That is up +5% on the projected 2033 average. That marks a +178% change versus current levels. Momentum favours further upside here.
By 2035, NVS could reach as high as $671.59, with a base case around $460.79 and support toward $340.92 — roughly +205% from $151.12. Buyers look set to stay in control over this stretch.
Expect NVS to range from $494.00 to $1,063.18 through 2040. The $696.29 average target implies a +361% move from current prices. That is up +51% on the projected 2035 average. Momentum favours further upside here.
The NVS price prediction for 2050 points to an average of $1,522.86 (low $1,007.57, high $2,491.81) — a potential gain of +908% on today's $151.12. Buyers look set to stay in control over this stretch.
Investing $1,000 in NVS today (≈ 6.617258 NVS) could be worth
$10,077.16
+$9,077.16 (+908%) by 2050 · US Dollar
Based on the average projected NVS price of $1,522.86 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NVSwould be worth at today's price.
$1,000 invested in NVS on May 27, 2025 (≈ 8.833142 NVS) would be worth
$1,334.86
+$334.86 (+33.5%) today · 1.33× · US Dollar
Based on a NVS entry price of $113.21 vs. today's $151.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $150.45 | $1,004.45 | +0.4% |
| 1 month ago | $144.19 | $1,048.06 | +4.8% |
| 3 months ago | $165.51 | $913.06 | -8.7% |
| 6 months ago | $130.4 | $1,158.9 | +15.9% |
| 1 year ago | $113.21 | $1,334.86 | +33.5% |
| All time (5.0y) ago | $88.12 | $1,714.93 | +71.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NVS forecast.
Our base-case forecast reaches $300.00 around 2030.
Implied market cap at $300.00: $572.43B
Across the multi-year forecast, the average price is projected to climb from $152.01 in 2026 to well above $1,500 by 2050, with substantial upside implied by rising targets. The 2030 forecast shows an average of $316.89 and an implied ROI of 108.5% with a bullish sentiment, and the 2040 forecast projects an average of $716.08 with a 371.1% ROI, still bullish. By 2050, the average is expected to reach $1,581.26 with a 940.2% ROI, continuing a bullish trajectory.
The interim years 2027–2029 show progressively higher averages: 2027 $189.20 (ROI 24.5%), 2028 $230.90 (ROI 51.9%), 2029 $278.81 (ROI 83.4%). These figures illustrate a consistent upward path under a bullish sentiment, though they are estimates and not guarantees. Investors should consider the inherent uncertainty in long-term forecasts and the potential for market volatility.
Tap a question to reveal the answer.
Current Price: $152.01; Market Cap: $290.05B; Rank: 46.
2030 forecast: min $247.11, avg $316.89, max $432.93; ROI 108.5%; sentiment BULLISH.
2050 forecast: min $1,046.12, avg $1,581.26, max $2,587.58; ROI 940.2%; sentiment BULLISH.
Sentiment BULLISH; RSI(14) 60; SMA50 $149.70; SMA200 $139.95; 30-day range $142.24–$162.46; support $142.94; resistance $154.47.
2027 forecast: min $154.52, avg $189.20, max $242.53; ROI 24.5%; sentiment BULLISH.
Novartis AG Community Discussion
0Share your Novartis AG price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.